Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06907329). This is a study registration, not published results. Lead sponsor: Qing Su. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 124 participants (ACTUAL). Conditions: Immunosenescence, Overweight, Obesity, Metabolic Dysfunction-Associated Fatty Liver Disease, Prediabetic State, Diabetes Mellitus, Type 2. Interventions: DIETARY_SUPPLEMENT: NMN; DIETARY_SUPPLEMENT: Placebo. Primary outcome measures: Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27-CD28- T Cells Among Total CD3+CD8+ T Cells , Baseline and Week 26. Brief summary: This study evaluates whether nicotinamide mononucleotide (NMN) sustained-release tablets affect markers of immune system aging in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. It compares NMN, 1,000 mg once daily for 26 weeks, with a matching placebo. The main assessment is the change from baseline in the proportion of a blood T-cell population associated with immune system aging. The study also evaluates liver fat, blood sugar regulation, body composition, other immune and metabolic markers, and cardiorespiratory fitness, together with laboratory measures of safety.